5th Pharmacology & Drug Development Congress
  • Follow

Accepted Abstracts

Pyrazinamide Induced Hyperuricemia in Tuberculosis Patients: An Observational Study

Shalini Sivadasan*, Giffin Tomy, Janet Maria James, Saranya Ponraj
KMCH College of Pharmacy, India

Citation: Sivadasan S, Tomy G, James JM, Venugopal J, Ponraj S (2020) Pyrazinamide Induced Hyperuricemia in Tuberculosis Patients:  An Observational Study. SciTech Central Pharma 2020. Mauritius

Received: November 24, 2019         Accepted: November 29, 2019         Published: November 29, 2019


Tuberculosis is an infectious disease which is transmitted through the air and damages the lungs and other parts in the human body. Pyrazinamide, an antitubercular drug, inhibits renal tubular excretion of urate by inhibiting its renal tubular secretion, resulting in some degree of hyperuricemia that is often asymptomatic. The objective of the study was to evaluate pyrazinamide induced hyperuricemia among tuberculosis patients. This prospective observational study was carried out among patients diagnosed with tuberculosis aged between 18 year to 65 years at Kovai Medical Center and Hospital, after the KMCH ethics committee approval (Ref: EC/AP/666/02/2019). A total of 52 patients who met the inclusion criteria were included in the study. It was found that in 75% (39) of the patients the uric acid level was increased of which 94.87% (37) of the patients were treated with febuxostat. Among those patients who showed hyperuricemia, only two patients had their uric acid level between 6.5-8 for consecutive three weeks of review and were not treated with febuxostat whereas, in 35 patients febuxostat was  in 2nd week and in 2 patients it was started in 3rd week. Febuxostat was used to treat hyperuricemia only among those patients who had complaints of severe pain or if their uric acid was more than 8. This study concluded that there is a significant increase observed in serum uric acid level induced by pyrazinamide in the second week after the initiation of antitubercular treatment and there is a need of monitoring uric acid levels in all patients receiving pyrazinamide so that hyperuricemia is not ignored while treating these patients and thereby improve the patient care.